GleamWall
中文EN

COSM Cosmos Health Inc.

Wholesale-Drugs, Proprietaries & Druggists' Sundries · Nasdaq · SEC CIK 1474167 · Fiscal year ends 12/31

Financial factors as of 2026-06-30 (2026Q2), TTM = sum of the last four quarters

Growth

TTM revenue YoY33.8%
TTM net income YoY-13.1%
TTM EPS YoY35.6%
Revenue 3-yr CAGR14.8%
Net income 3-yr CAGR—

Margins

Gross margin10.3%
Operating margin-24.9%
Net margin-33.1%
FCF margin-13.5%
EBITDA margin-23.0%

Returns

ROE-104.0%
ROA-39.6%
ROIC (approx.)-54.8%
Asset turnover1.20x

Leverage & solvency

Liabilities / assets66.4%
Debt / equity0.15x
Current ratio1.05x
Interest coverage-7.80x

Cash quality & payout

Operating cash flow / net income0.40x
Accruals ratio-23.6%
Payout ratio—
Capex / revenue0.1%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$65.27M$54.43M$53.38M$50.35M$56.24M
Cost of revenue$57.38M$50.12M$49.03M$44.39M$47.91M
Gross profit$7.90M$4.31M$4.35M$5.96M$8.33M
R&D expense$519,363$533,293$164,859——
SG&A expense$15.62M$11.73M$19.64M$10.18M$9.21M
Operating income-$16.70M-$15.54M-$21.83M-$7.47M-$4.53M
Interest expense$1.90M$1.01M$866,476$2.35M$2.82M
Pretax income-$19.14M-$16.18M-$18.54M-$13.06M-$7.85M
Income tax$0$0$0-$775,051$114,010
Net income-$19.14M-$16.18M-$18.54M-$13.83M-$7.96M
EBITDA-$15.34M-$14.33M-$21.22M-$7.29M-$4.18M
EPS (basic)-0.63-1.17-2.15-33.16-23.74
EPS (diluted)-0.63-1.17-2.15-33.16-23.74
Weighted avg. shares (diluted)30.29M19.15M—1.93M656,933
Banking
Noninterest expense———$216,182—
Balance sheet
Cash & equivalents$715,674$315,105$3.83M$20.75M$286,487
Short-term investments$46,158$21,148$20,075$14,881$11,468
Receivables$19.63M$13.48M$19.76M$23.69M—
Inventory$5.78M$4.36M$4.79M$3.45M$3.15M
Current assets$38.39M$25.46M$36.61M$56.37M$39.83M
PP&E, net$10.58M$9.69M$10.33M$1.82M$1.89M
Goodwill$49,697$49,697$49,697$49,697$49,698
Intangibles$7.52M$7.71M$7.76M$657,217$436,069
Total assets$65.48M$54.31M$66.01M$68.04M$49.43M
Current liabilities$38.27M$25.76M$24.32M$21.75M$29.93M
Short-term debt——$1.91M——
Long-term debt$3.78M$4.11M$1.33M$5.02M$477,637
Total debt$3.78M$4.11M$3.24M$5.02M$477,637
Total liabilities$47.05M$29.78M$29.97M$28.38M$45.05M
Shareholders' equity$18.42M$24.53M$36.04M$39.28M$4.38M
Net debt$3.06M$3.79M-$597,560-$15.73M$191,150
Shares outstanding41.07M23.60M15.90M10.59M686,283
Cash flow statement
Operating cash flow-$8.45M-$7.72M-$15.64M-$14.87M-$7.10M
Capital expenditure$55,675$418,075$1.31M$74,207$581,398
Free cash flow-$8.50M-$8.14M-$16.95M-$14.94M-$7.68M
Investing cash flow-$2.01M-$798,269-$13.76M-$21,497-$826,817
Financing cash flow$14.06M$5.05M$12.69M$35.05M$7.27M
Depreciation & amortization$1.36M$1.22M$614,377$188,890$352,422
Stock-based compensation$2.31M$1.69M$577,931$24,401$5.90M
Share buybacks—$0$100,452—$376,863

Free plan shows the latest 5 periods; Pro shows all 18 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-19 06:28.